127 related articles for article (PubMed ID: 25343521)
1. Single nucleotide polymorphisms in noncoding regions of Rad51C do not change the risk of unselected breast cancer but they modulate the level of oxidative stress and the DNA damage characteristics: a case-control study.
Gresner P; Gromadzinska J; Jablonska E; Stepnik M; Zambrano Quispe O; Twardowska E; Wasowicz W
PLoS One; 2014; 9(10):e110696. PubMed ID: 25343521
[TBL] [Abstract][Full Text] [Related]
2. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.
Vuorela M; Pylkäs K; Hartikainen JM; Sundfeldt K; Lindblom A; von Wachenfeldt Wäppling A; Haanpää M; Puistola U; Rosengren A; Anttila M; Kosma VM; Mannermaa A; Winqvist R
Breast Cancer Res Treat; 2011 Dec; 130(3):1003-10. PubMed ID: 21750962
[TBL] [Abstract][Full Text] [Related]
3. Combined effect of polymorphisms in Rad51 and Xrcc3 on breast cancer risk and chromosomal radiosensitivity.
Vral A; Willems P; Claes K; Poppe B; Perletti G; Thierens H
Mol Med Rep; 2011; 4(5):901-12. PubMed ID: 21725594
[TBL] [Abstract][Full Text] [Related]
4. Rad51C: a novel suppressor gene modulates the risk of head and neck cancer.
Gresner P; Gromadzinska J; Twardowska E; Rydzynski K; Wasowicz W
Mutat Res; 2014 Apr; 762():47-54. PubMed ID: 24631219
[TBL] [Abstract][Full Text] [Related]
5. Rad51 paralogs and the risk of unselected breast cancer: A case-control study.
Grešner P; Jabłońska E; Gromadzińska J
PLoS One; 2020; 15(1):e0226976. PubMed ID: 31905201
[TBL] [Abstract][Full Text] [Related]
6. RAD51C is a susceptibility gene for ovarian cancer.
Pelttari LM; Heikkinen T; Thompson D; Kallioniemi A; Schleutker J; Holli K; Blomqvist C; Aittomäki K; Bützow R; Nevanlinna H
Hum Mol Genet; 2011 Aug; 20(16):3278-88. PubMed ID: 21616938
[TBL] [Abstract][Full Text] [Related]
7. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.
Thompson ER; Boyle SE; Johnson J; Ryland GL; Sawyer S; Choong DY; kConFab ; Chenevix-Trench G; Trainer AH; Lindeman GJ; Mitchell G; James PA; Campbell IG
Hum Mutat; 2012 Jan; 33(1):95-9. PubMed ID: 21990120
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families.
Johnson J; Healey S; Khanna KK; ; Chenevix-Trench G
Breast Cancer Res Treat; 2011 Aug; 129(1):255-63. PubMed ID: 21533530
[TBL] [Abstract][Full Text] [Related]
9. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
[TBL] [Abstract][Full Text] [Related]
10. A role for XRCC4 in age at diagnosis and breast cancer risk.
Allen-Brady K; Cannon-Albright LA; Neuhausen SL; Camp NJ
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1306-10. PubMed ID: 16835328
[TBL] [Abstract][Full Text] [Related]
11. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.
De Leeneer K; Van Bockstal M; De Brouwer S; Swietek N; Schietecatte P; Sabbaghian N; Van den Ende J; Willocx S; Storm K; Blaumeiser B; Van Asperen CJ; Wijnen JT; Leunen K; Legius E; Michils G; Matthijs G; Blok MJ; Gomez-Garcia E; De Paepe A; Tischkowitz M; Poppe B; Claes K
Breast Cancer Res Treat; 2012 May; 133(1):393-8. PubMed ID: 22370629
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risk and common single nucleotide polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3, NBS1 and RAD51.
Silva SN; Tomar M; Paulo C; Gomes BC; Azevedo AP; Teixeira V; Pina JE; Rueff J; Gaspar JF
Cancer Epidemiol; 2010 Feb; 34(1):85-92. PubMed ID: 20004634
[TBL] [Abstract][Full Text] [Related]
14. Impact of genetic polymorphisms in base excision repair genes on the risk of breast cancer in a Korean population.
Kim KY; Han W; Noh DY; Kang D; Kwack K
Gene; 2013 Dec; 532(2):192-6. PubMed ID: 24076439
[TBL] [Abstract][Full Text] [Related]
15. Interaction between genetic variations in DNA repair genes and plasma folate on breast cancer risk.
Han J; Hankinson SE; Zhang SM; De Vivo I; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):520-4. PubMed ID: 15066914
[TBL] [Abstract][Full Text] [Related]
16. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
[TBL] [Abstract][Full Text] [Related]
17. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis.
Pearce CL; Hirschhorn JN; Wu AH; Burtt NP; Stram DO; Young S; Kolonel LN; Henderson BE; Altshuler D; Pike MC
J Natl Cancer Inst; 2005 Jan; 97(1):51-9. PubMed ID: 15632380
[TBL] [Abstract][Full Text] [Related]
18. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.
Haiman CA; Stram DO; Pike MC; Kolonel LN; Burtt NP; Altshuler D; Hirschhorn J; Henderson BE
Hum Mol Genet; 2003 Oct; 12(20):2679-92. PubMed ID: 12944421
[TBL] [Abstract][Full Text] [Related]
20. Association between DNA damage, DNA repair genes variability and clinical characteristics in breast cancer patients.
Synowiec E; Stefanska J; Morawiec Z; Blasiak J; Wozniak K
Mutat Res; 2008 Dec; 648(1-2):65-72. PubMed ID: 18977234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
